Finance

Lists
Why is EVMN down 2,27%?
Dive Deeper
EVMN:NYSE
Evommune Inc
USD 6,25
-2,27%
(-0,14) 1D
USD 6,25
0,00% (0,00)
After hours
Closed: 9 Okt., 16:00:02 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EVMN...
Open
USD 6,40
High
USD 6,44
Low
USD 6,18
Mkt. cap
226,83 m
Avg. vol.
884,46 k
Volume
557,96 k
52-wk high
USD 33,20
52-wk low
USD 6,02
EPS
-USD 2,89
Shares outstanding
36,29 m
No. of employees
48
Open
USD 6,40
High
USD 6,44
Low
USD 6,18
Mkt. cap
226,83 m
Avg. vol.
884,46 k
Volume
557,96 k
52-wk high
USD 33,20
52-wk low
USD 6,02
EPS
-USD 2,89
Shares outstanding
36,29 m
No. of employees
48
News stories
From web sources and news partners
About Evommune Inc
CEO-
Employees48
Founded2020
HeadquartersPalo Alto, Kalifornië, Verenigde State van Amerika
Sector-
Websiteevommune.com
Analyst ratings
Based on 13 analysts giving stock ratings to EVMN in the past 3 months
Strong buy
Buy
10
Hold
3
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for EVMN in the last 3 months.
Highest
Current USD 6,25
USD 30,00 (+380,00%)
Average
USD 22,40 (+258,40%)
Lowest
USD 8,00 (+28,00%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
UBS
Hold
Initiated
USD 8,00
+28%
10/11/2026
Mitchell Kapoor
H.C. Wainwright
Hold
Reiterated
-
-
10/05/2026
Prakhar Agrawal
Cantor Fitzgerald
Buy
Maintained
-
-
09/17/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
USD 23,00
+268%
09/09/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
USD 30,00
+380%
09/09/2026
Serge Belanger
Needham
Buy
Maintained
USD 28,00
+348%
09/09/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
USD 22,00
+252%
09/10/2026
Martin Auster
Raymond James
Buy
Maintained
USD 18,00
+188%
09/09/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
USD 26,00
+316%
09/09/2026
Brian Abrahams
RBC Capital
Buy
Maintained
USD 21,00
+236%
09/08/2026
Matt Phipps
William Blair
Hold
Maintained
-
-
09/09/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
USD 22,00
+252%
08/10/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
USD 26,00
+316%
08/10/2026
Last report
06 Aug. 2026
Fiscal period
Q2 2026
-USD 0,89 / -USD 0,67
-32,84%miss
Revenue / Est. (USD)
- / 1,14 m
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
10,00 m
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
19,64 m
20,40 m
17,32 m
26,41 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,69 m
9,31 m
6,64 m
8,48 m
Operating expense
23,33 m
29,72 m
23,95 m
34,90 m
Total operating expenses
23,33 m
29,72 m
23,95 m
34,90 m
Operating income
-13,33 m
-29,72 m
-23,95 m
-34,90 m
Other non operating income
-9,00 k
-
-4,00 k
-2,00 k
EBT including unusual items
-12,48 m
-28,27 m
-21,67 m
-32,25 m
EBT excluding unusual items
-12,48 m
-28,27 m
-21,67 m
-32,25 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12,48 m
-28,27 m
-21,67 m
-32,25 m
Net profit margin
-124,75%
-
-
-
Earnings per share
-8,07
-1,43
-0,64
-0,89
Interest and investment income
862,00 k
1,44 m
2,28 m
2,65 m
Interest expense
-
-
-
-
Net interest expenses
862,00 k
1,44 m
2,28 m
2,65 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-13,02 m
-29,39 m
-23,60 m
-34,34 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme